drugset / Trial / NCT05546723
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Phase 1
Recruiting
30 enrolled
Luminary Therapeutics
Case Western Reserve University · collabThe Cleveland Clinic · collab
NaSequentialOpen-labelTreatment
Summary
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Timeline
- Start
- 2024-03-13
- Primary completion
- 2025-07-31
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAFF CAR-T | Cell therapy | — | — |